Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

283 trials

NCT07443514
Recruiting
Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma
Not applicable · Slovenia · 1 site
Registry update: 2 Mar 2026
NCT05107674
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · United Kingdom, United States · 17 sites
Registry update: 9 Sept 2025
NCT05018520
Recruiting
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Phase 3 · China · 1 site
Registry update: 11 May 2026
NCT05006716
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Phase 1/2 · Australia, Brazil, Canada, China, Germany, Spain, France, United Kingdom, Georgia, Italy, Japan, South Korea, Moldova, Sweden, United States · 114 sites
Registry update: 5 Oct 2026
NCT04670029
Recruiting
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
Phase 3 · France · 5 sites
Registry update: 8 Oct 2021
NCT05552937
Recruiting
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Phase 2 · China · 1 site
Registry update: 23 Sept 2022
NCT05040555
Recruiting
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
Not applicable · China · 1 site
Registry update: 16 Sept 2021
NCT04844866
Recruiting
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · Austria, Belgium, Czechia, Germany, Spain, Finland, France, Croatia, Hungary, Italy, Lithuania, Netherlands, Poland, Portugal, Sweden · 60 sites
Registry update: 10 Jun 2026
Conflicting statuses (not updated in the registry for 5 months)
NCT04491370
Recruiting
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/2 · United States · 1 site
Registry update: 15 Apr 2026
NCT04775745
Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 · United States · 4 sites
Registry update: 13 Feb 2026
NCT04920617
Recruiting
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · Australia, Canada, Spain, France, Hungary, New Zealand, Poland, Romania, Serbia, United States · 50 sites
Registry update: 7 Apr 2023
NCT04792489
Recruiting
DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 · Canada, Croatia, Hungary, United States · 34 sites
Registry update: 13 Jul 2026
Conflicting statuses (not updated in the registry for 3 months)
NCT04139304
Recruiting
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Early phase 1 · United States · 9 sites
Registry update: 28 Oct 2026
NCT04830137
Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · United States · 16 sites
Registry update: 20 Mar 2026
NCT04914091
Recruiting
Quality Of Life and Drug Use in Patients With CAR-T Cells
Not applicable · France · 1 site
Registry update: 28 Jan 2026
NCT04442412
Recruiting
Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy
Phase 3 · Italy · 44 sites
Registry update: 26 Aug 2022
Conflicting statuses (not updated in the registry for 50 months)
NCT04836507
Recruiting
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/2 · South Korea · 2 sites
Registry update: 1 Jul 2026
NCT04502394
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Phase 1/2 · Australia, Belgium, Switzerland, Czechia, France, United Kingdom, Italy, South Korea, Poland, Portugal, United States · 45 sites
Registry update: 4 Aug 2022
NCT04329728
Recruiting
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/2 · United States · 11 sites
Registry update: 15 Apr 2026
NCT04627753
Recruiting
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Phase 2 · South Korea · 1 site
Registry update: 23 Apr 2026

Ordered by registry start date. Freshness and sponsorship never change the order.